Ted D. Kellner has reported several stock transactions involving AIM ImmunoTech Inc., as detailed in his recent SEC filing. This event is significant as it showcases the ongoing changes in ownership stakes within the biological products sector, which can influence investor sentiment and market dynamics.

Background

KELLNER TED D is an individual investor associated with AIM ImmunoTech Inc., a company specializing in biological products. AIM ImmunoTech is listed under the SIC code 2836, indicating its focus on biological products without diagnostic substances. The company is incorporated in Delaware and has a fiscal year ending on December 31. Recent filings by Kellner include a Form 4 submitted on November 20, 2026, along with several other filings throughout 2025 and 2024.

What the Filing Says

The filing, dated November 20, 2026, reveals that Kellner conducted multiple transactions on November 18, 2026. He disposed of a total of 17,526 shares of AIM ImmunoTech common stock at a price of $0.136 per share. Following these transactions, Kellner retains ownership of 19,714 shares.

Impact

This update may affect various stakeholders, including investors and analysts monitoring AIM ImmunoTech's stock activity. Kellner's transactions reflect his management role in multiple investment entities, including Kelvest ILP and the Beta Fund Investment Club, where he serves as manager. His actions may signal confidence or caution regarding the company's future prospects.

What's Next

The filing does not say what happens next.